Literature DB >> 2251520

Hodgkin's disease: the role of bone marrow transplantation.

J M Vose1, P J Bierman, J O Armitage.   

Abstract

Because results with conventional salvage therapy remain disappointing, the approach of using high-dose therapy and bone marrow transplantation has gained increasing support in recent years. Several trials have now been reported using various conditioning regimens and hematopoietic rescue sources. Although it is not clear which high-dose chemotherapy is the best conditioning regimen, many of the trials contain patients who are long-term disease-free survivors using this therapeutic approach. As more experience is gained with this therapy, the patient population for which it offers the best results will be better defined. High-dose therapy and bone marrow transplantation has been shown to offer better long-term disease-free survival to patients who are transplanted after failing one or two chemotherapy regimens, have good performance status, and still have chemotherapy-sensitive disease. For research to continue in this area, it is important that patients who are otherwise eligible for high-dose therapy and bone marrow transplantation participate in clinical trials to address the unanswered questions concerning high-dose therapy and bone marrow transplantation.

Entities:  

Mesh:

Year:  1990        PMID: 2251520

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  2 in total

1.  The use of soybean agglutinin (SBA) for bone marrow (BM) purging and hematopoietic progenitor cell enrichment in clinical bone-marrow transplantation.

Authors:  A Nagler; S Morecki; S Slavin
Journal:  Mol Biotechnol       Date:  1999-04       Impact factor: 2.695

2.  EPIC: an effective low toxicity regimen for relapsing lymphoma.

Authors:  T Hickish; A Roldan; D Cunningham; J Mansi; S Ashley; V Nicolson; M E Gore; D Catovsky; I E Smith
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.